Stock Financial Ratios and Split History

MTNB / Matinas Biopharma Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)101.89
Enterprise Value ($M)94.59
Book Value ($M)10.68
Book Value / Share0.11
Price / Book7.63
NCAV ($M)4.20
NCAV / Share0.04
Price / NCAV24.28
Income Statement (mra) ($M)
Net Income-15.49
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio3.33
Current Ratio3.33
Share Statistics
Common Stock Shares Outstanding93,371,129
Common Shares Outstanding93,478,602
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.45
Return on Assets (ROA)-1.58
Return on Equity (ROE)-2.17
Identifiers and Descriptors
Central Index Key (CIK)1582554
Industry Groups
SIC 2834 - Pharmaceutical Preparations

Split History

Stock splits are used by company's to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can issue all shareholders an extra share, thereby halving the price. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted

Coming soon

Peers - Pharmaceutical Preparations (2834)

Related News Stories

BRIEF-Matinas BioPharma says qtrly loss per share $0.04‍​

2017-11-15 reuters
* Matinas BioPharma Holdings Inc - qtrly loss per share $0.04‍​ Source text for Eikon: Further company coverage: (10-0)

3 Companies Spearheading the Antibiotics Space in 2018

2017-11-10 247wallst
This may turn out to be a pivotal year in antibiotic development, after decades of dramatic decline in the space. While 1980 to 1984 saw 18 new antibiotic approvals, the period from 2005 and 2012 saw only four. As resistance becomes a more and more pressing issue, now even threatening to make routine surgery very difficult due to infection concerns, the need for new antibiotics is becoming very urgent. (64-2)

CUSIP: 576810105